Pediatric Formulations Of Oral Oncologics Sought By FDA
Executive Summary
FDA is trying to encourage developers of oral cancer agents to create pediatric formulations as part of the development process
You may also be interested in...
FDA Pediatric Study Bill Clears Senate, Will Sunset With Exclusivity Grants
Legislation restoring FDA's authority to require drug sponsors to conduct trials in children would sunset at the same time as the pediatric exclusivity incentive program under a bill adopted by the Senate July 23
Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
AstraZeneca's first chance to secure traditional approval for Iressa will be a randomized trial assessing symptom improvement in non-small cell lung cancer due to be submitted to the agency by June 2005
Pharmacogenetic Test Should Be Added To 6-MP Label, FDA Cmte. Says
GlaxoSmithKline's Purinethol (mercaptopurine) should include labeling recommending use of pharmacogenetic testing to guide dosing, the Clinical Pharmacology Subcommittee of FDA's Pharmaceutical Science Advisory Committee concluded at its Oct. 23 meeting